Clinical Trials Logo

Melanoma Stage III clinical trials

View clinical trials related to Melanoma Stage III.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06204991 Not yet recruiting - Melanoma Clinical Trials

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

ADP-TILIL7
Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

The primary objective of this Phase 1 clinical trial is to evaluate the feasibility and tolerability of a novel generation of gene-modified tumor infiltrating lymphocytes (TILs) in a cohort of 10 patients aged 18-75 diagnosed with unresectable or metastatic melanoma. TILs will undergo transduction with the Interleukin-7 (IL-7) gene, for IL-7 production upon antigen engagement. Participants will undergo: - screening - tumor operation following autologous TIL production (incl. transduction) - takes approximately 4-6 weeks - admission for lymphodepleting chemotherapy (Cyclophosphamide and Fludarabine phosphate), TIL infusion and high-dose IL-2 infusions for a maximum of 6 doses - Following treatment, patients will undergo systematic and regularly planned assessments, encompassing clinical evaluation, biochemistry analyses, and PET/CT scans. This thorough follow-up regimen will be continued until any of the following events occur: progressive disease, withdrawal from study, or end of study, which spans a duration of 15 years for trials involving genetically modified organisms.

NCT ID: NCT05827770 Not yet recruiting - Melanoma Stage III Clinical Trials

The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

This study is being conducted to explore the efficacy and safety of neoadjuvant toripalimab combined with temozolomide in resectable stage III melanoma.

NCT ID: NCT05467137 Not yet recruiting - Melanoma Stage III Clinical Trials

Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG

MelanooMSOT
Start date: September 2022
Phase: Phase 4
Study type: Interventional

In this study the investigators try to identify the sentinel lymph node in patients with stage Ib-III melanoma in a non-invasive manner without the use of a radioactive tracer by using the new MSOT technology.